GlassScriptPhysician profile
Andrew Lazin
NPI 1881686079
$647.12
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $422 · 2020: $177 · 2021: $48.15.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $147.21 | 2019-2020 | |
| Vifor Pharma, INC. | $146.53 | 2019-2020 | |
| Fresenius USA Marketing, INC. | $90.84 | 2019-2021 | |
| Mallinckrodt Enterprises LLC | $74.63 | 2019 | |
| Opko Pharmaceuticals, LLC | $44.08 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $39.59 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $36.33 | 2019-2020 | |
| Akebia Therapeutics INC | $35.56 | 2019 | |
| Travere Therapeutics, INC. | $18.79 | 2020 | |
| Glaxosmithkline, LLC. | $13.56 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Lazin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.